<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56909">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01756833</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00051170</org_study_id>
    <secondary_id>R01AG037120</secondary_id>
    <nct_id>NCT01756833</nct_id>
  </id_info>
  <brief_title>Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial</brief_title>
  <acronym>N-TA^3CT</acronym>
  <official_title>Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine if doxycycline (100 mg bid) will inhibit (by
      at least 40%) the increase in greatest transverse diameter of small abdominal aortic
      aneurysms (3.5-5.0 cm in men, 3.5-4.5 cm in women) over a 24-month period of observation in
      comparison to a placebo-treated control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-TA^3CT is a randomized, double-blind, placebo-controlled test of the hypothesis that
      doxycycline 100 mg bid, will reduce the rate of increase of maximum transverse diameter of
      small (3.5-5.0 cm among men and 3.5 to 4.5 cm among women) abdominal aortic aneurysms. The
      primary outcome is abdominal aortic aneurysm (AAA) maximum transverse diameter determined by
      CT scans at two-year follow-up with allowance for baseline (pre-randomization) diameter.
      Based on an anticipated growth rate of 2.5 mm per year in the placebo group and the current
      threshold at which surgical intervention will be offered to trial participants, (5.5 cm in
      men, 5.0 cm in women), the upper limit of AAA size for inclusion has been set at 5.0 cm for
      men and 4.5 cm for women. Among these subjects, the threshold for repair would be exceeded
      only by those exhibiting persistent growth. Secondary outcomes will determine if doxycycline
      affects other measures, e.g., MMP-9 levels in plasma and whether these effects are related
      to aneurysm growth. Fifteen clinical sites have identified pools of over 900 patients with
      small aneurysm who meet the proposed inclusion/exclusion criteria. Two hundred forty-eight
      patients will be randomized to placebo or doxycycline and their aneurysms followed for
      change in diameter at six-month intervals using CT imaging. The alternative hypothesis is
      that doxycycline will inhibit the expansion rate by 40% during the two years of observation.
      Patients enrolling in N-TA^3CT must be able to give consent for their participation
      themselves and meet study eligibility criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary outcome is growth in abdominal aortic aneurysm (AAA) maximum transverse diameter determined by CT scans at two-year follow-up with allowance for baseline (pre-randomization) diameter.</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on an anticipated growth rate of 2.5 mm per year in the placebo group and the current threshold at which surgical intervention will be offered to trial participants, (5.5 cm in men, 5.0 cm in women), the upper limit of AAA size for inclusion has been set at 5.0 cm for men and 4.5 cm for women. Among these subjects, the threshold for surgical repair would be exceeded only by those exhibiting persistent growth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will determine if doxycycline affects other measures, e.g., MMP-9 levels in plasma, and whether these effects are related to aneurysm growth.</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcomes will derive from central, Imaging Core Laboratory analyses of the CT scans performed every six months on patients and from the clinical follow-up of randomized patients, from clinical observation, local laboratory findings, study visit quality of life assessments, and from biomarker analyses to be performed in the Biomarkers Core Laboratory (e.g., changes from initial matrix metalloproteinase (MMP-9) levels, and matrix metalloproteinase (MMP-9) levels at 24 months of follow-up).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will determine if doxycycline affects other measures, e.g., Interferon-gamma levels, and whether these effects are related to aneurysm growth.</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcomes will derive from central, Imaging Core Laboratory analyses of the CT scans performed every six months on patients and from the clinical follow-up of randomized patients, from clinical observation, local laboratory findings, study visit quality of life assessments, and from biomarker analyses to be performed in the Biomarkers Core Laboratory (e.g., changes from initial Interferon-gamma levels, and Interferon-gamma levels at 24 months of follow-up).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Aneurysm volume and other characteristics</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Aneurysm rupture</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Surgical intervention</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>Three and one-half years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Aneurysm</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg capsules, twice a day, for a period of two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mg capsules, twice a day, for a period of two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>doxycycline hyclate</other_name>
    <other_name>Vibramycin</other_name>
    <other_name>Oracea</other_name>
    <other_name>Adoxa</other_name>
    <other_name>Atridox and others</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 55 years of age or older, women post-surgical menopause or at      least two
             years since last menses if natural menopause.

          -  CT scan documented infrarenal abdominal aortic aneurysm with maximum transverse
             diameter larger than 35 mm and no greater than 50 mm, in men, and larger than 35 mm
             and no greater than 45 mm in women.

        Exclusion Criteria:

          -  Patients will be excluded from the study if they are unable to give their own
             informed consent to participate.

          -  have symptoms related to abdominal aortic aneurysm.

          -  have other intra-abdominal vascular pathology that may require repair within 24
             months (e.g., renal artery stenosis, large iliac artery aneurysms, iliac occlusive
             disease, aneurysmal involvement of the renal artery).

          -  have had previous abdominal aortic aneurysm repair by open surgical or endovascular
             technique.

          -  have an active malignancy with life expectancy less than two years.

          -  have an allergy to tetracycline.

          -  are currently or have been recently treated (previous six months) with tetracycline
             derivatives.

          -  they are currently taking anti-seizure medicines metabolized by pathways influenced
             by doxycycline (e.g., carbamazepine, phenytoin, and barbiturates).

          -  stage II hypertension (patients whose blood pressure is persistently in the range of
             systolic &gt; 160 mm Hg or diastolic &gt; 100 mm Hg despite primary physician's best effort
             to achieve adequate therapy.

          -  have dialysis dependent renal failure or impending dialysis treatment for renal
             insufficiency.

          -  have a chronic infection requiring long-term (&gt; 2 weeks) antibiotics.

          -  have known genetic syndromes responsible for the abdominal aortic aneurysm (e.g.,
             Marfan's Syndrome).

          -  are under treatment with systemic immunosuppressive agents.

          -  could become pregnant.

          -  are not good candidates for clinical trial participation.

          -  are enrolled in another clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Terrin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore County</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard T Baxter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Matsumura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Curci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael L Terrin, MD</last_name>
    <phone>410-706-6139</phone>
    <email>mterrin@epi.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Lefever</last_name>
    <phone>410-706-4411</phone>
    <email>alefever@epi.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Mills, MD</last_name>
      <phone>520-626-6670</phone>
      <email>jmills@surgery.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Leigh, RN</last_name>
      <phone>520-626-4845</phone>
      <email>hleigh@surgery.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Mills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Katzen, MD</last_name>
      <phone>786-596-5990</phone>
      <email>BARRYK@baptisthealth.net</email>
    </contact>
    <contact_backup>
      <last_name>Susan Arp</last_name>
      <phone>786-596-5972</phone>
      <email>susanar@baptisthealth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Barry Katzen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida Health Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murray Shames, MD</last_name>
      <phone>813-259-0921</phone>
      <email>mshames@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephenie Yapchanyk, RN</last_name>
      <phone>813-259-0683</phone>
      <email>syapchan@health.usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Murray Shames, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Pearce, MD</last_name>
      <phone>312-695-2716</phone>
      <email>wpearce@nmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Endo</last_name>
      <phone>312-695-2928</phone>
      <email>mendo@nmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Pearce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Crawford, MD</last_name>
      <phone>410-328-5840</phone>
      <email>rcrawford@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debbie Nesbitt, RN</last_name>
      <phone>410-605-7435</phone>
      <email>debbie.nesbitt@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Wyers, MD</last_name>
      <phone>617-632-9956</phone>
      <email>mwyers@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Trovato, RN</last_name>
      <phone>617-632-7488</phone>
      <email>mtrovato@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Wyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Eliason, MD</last_name>
      <phone>734-936-5786</phone>
      <email>jonaelia@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Blackburn</last_name>
      <phone>734-936-8556</phone>
      <email>susablac@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Eliason, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Rectenwald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Thompson, MD</last_name>
      <phone>314-362-7410</phone>
      <email>thompson@wudosis.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Wille, RN</last_name>
      <phone>314-362-6217</phone>
      <email>willej@wudosis.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason MacTaggart, MD</last_name>
      <phone>402-559-4395</phone>
      <email>jmactaggart@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Taylor, RN</last_name>
      <phone>402-559-3935</phone>
      <email>kttaylor@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jason MacTaggart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James McKinsey, MD</last_name>
      <phone>212-342-3255</phone>
      <email>jfm2111@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diana Catz, PhD</last_name>
      <phone>212-342-4102</phone>
      <email>dsc6@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James McKinsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Lerner College of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Moneta, MD</last_name>
      <phone>503-494-7593</phone>
      <email>monetag@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Kryger, BS</last_name>
      <phone>503-494-7477</phone>
      <email>krygers@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Moneta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Elmore, MD</last_name>
      <phone>570-271-6369</phone>
      <email>jelmore@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Deetz, RN</last_name>
      <phone>570-214-9321</phone>
      <email>emdeetz@geisinger.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Elmore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Kraiss, MD</last_name>
      <phone>801-581-8301</phone>
      <email>larry.kraiss@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Maloney</last_name>
      <phone>801-585-3663</phone>
      <email>maria.maloney@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Larry Kraiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Michael Terrin, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>abdominal</keyword>
  <keyword>aortic</keyword>
  <keyword>aneurysm</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
